European Medicines Agency: A possible link between Johnson’s vaccine and rare blood clots

European Medicines Agency: A possible link between Johnson’s vaccine and rare blood clots
European Medicines Agency: A possible link between Johnson’s vaccine and rare blood clots
The European Medicines Agency’s Safety and Risks Committee has concluded that there is a possible link to rare venous thromboembolism and the COVID-19 vaccine developed by Johnson & Johnson’s Janssen company, in light of a review of new evidence from two studies and data collected while the vaccine is used in the context of vaccination campaigns. .

This warning is different from the extremely rare side effect of coagulopathy with thrombocytopenia, according to Bloomberg News.

Venous thromboembolism was already included in the Janssen vaccine risk management plan for COVID-19 as among the safety concerns to be investigated, based on the higher proportion of venous thromboembolism observed among the vaccinated versus placebo group in the study. The clinical major used to authorize this vaccine.

The Committee therefore recommends that venous thromboembolism as a rare side effect of Janssen vaccine against COVID-19 be included in the product information, along with a warning to raise awareness among healthcare workers and persons receiving the vaccine, especially those who may have an increased risk of venous thromboembolism. .

Source

European Medicines Agency link Johnsons vaccine rare blood clots

 
For Latest Updates Follow us on Google News
 

PREV A new jump is expected for “Bitcoin” .. up to 168 thousand dollars at this time
NEXT An Israeli company unveils a flying vehicle that can be used as a car